EXPRESS MAIL LABEL NO.: EV 333487354

6-3-04

PATENT

Attorney Docket No. 12636.260

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Jew

In re Application) <u>PATENT APPLICATION</u>
Inventor(s): LYONS, John))) A mt I I m id. 1622
Application No.: 10/071,849) Art Unit: 1623
Filed: February 7, 2002) Examiner: Devesh Khare
Title: Method for treating chronic myelogenous leukemia)

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

06/04/2004 SSESHE1 00000024 232415 10071849 01 FC:1806 180.00 DA

NIN O T MAN E	This s	tatemen	t qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
ATEMT & TRANS		(1)	It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d) OR
		(2)	It is being filed within 3 months of entry of a national stage OR
		(3)	It is being filed before the mail date of the first Office Action on the merits OR
		(4)	It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
. 🗵	the fil nation a first	ing date al stage Office	97(c). If this statement is being filed after the latest of: (1) three months beyond the of a national application; (2) three months beyond the date of entry of the as set forth in §1.491 in an international application; or (3) the mailing date of action on the merits, but before the mailing date of the earlier of a final office §1.113 or a notice of allowance under §1.311, then:
		a certi	fication as specified in §1.97(e) is provided below; or
			of \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included ne payment of other papers filed together with this statement.
	final o		97(d). If this statement is being filed after the mailing date of the earlier of a tion under §1.113 or a notice of allowance under §1.311, but before payment of then:
	A.	a certii	fication as specified in §1.97(e) is completed below; and
	B.	-	tion under 37 C.F.R. §1.97(d) requesting consideration of this statement is sted herewith; and
	C.		of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included the payment of other papers filed together with this statement.
	Copies		ch of the references listed on the attached Form PTO-1449 are enclosed
	Copies THAT		erences listed on the attached Form PTO-1449 are enclosed herewith EXCEPT
			w of the voluminous nature of references, and the likelihood that these are available to the Examiner in the file history of the parent application No.), copies are not enclosed herewith.
			of the foregoing publications are not available to the Examiner, Applicant will or to supply copies at the Examiner's request.
		accord	of only foreign patent documents and non-patent literature are enclosed in ance with 37 CFR 1.98 (a)(2). (The U:S. patents and each U.S. patent ation publication listed on the attached Form PTO-1449 are not enclosed



because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i).

	There are no listed references which are not in the English language.
	The relevance of those listed references which are not in the English language is as follows:
	Attached are copies of search report(s) from corresponding patent application(s) which are listed on the attached Submission Under MPEP 609 D.
	Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.
fees o	uthorization. The Commissioner is hereby authorized to charge the above-referenced f \$180.00 and charge any additional fees or credit any overpayment associated with this nunication to Deposit Account No. 23-2415 (Docket No. 12636.260).
	Respectfully submitted,
	WILSON SONSINI GOODRICH & ROSATI

By:_

Shirley Chen, Reg. No. 44,608

Dated:

 \boxtimes

650 Page Mill Road Palo Alto, CA 94304-1050

Tune 1, 200 4

(650) 493-9300

Customer No. 021971





Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. Department of Commerce

Inder the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known			
Substitute for	form 1449	A/PTO		Application No.	10/071,849		
		N DISCL		Filing Date	02/07/2002		
STATEMENT BY APPLICANT				First Named Inventor	Lyons		
(Use as many sheets as necessary)				Art Unit	1623		
				Examiner Name	Khare		
Sheet	1	Of	2	Attorney Docket No.	12636.260		

	U.S. PATENT DOCUMENTS						
		Document No.					
Examiner's Initials	Cite No. 1	Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		US-					
		US-					
		US-					
		US-		-			
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-		·	,		

		FOREIG	N PATENT DO	OCUMENTS		
		Foreign Patent Document				
Examiner's Initials	Cite No.1	Country Code ³ – Number ⁴ – Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		WO 02/069903	09/12/2002	Biocryst Pharmaceuticals, Inc.		
						_
						_
EXAMINER SIGNATURI			L	DATE CONSIDERED		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional) 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

der the paperwork	Reduction A	Act of 1995, no	persons required	U.S. F to respond to a collection of information unles	PTO/SB/08A (10-01) Approved for use through 10/31/2002. OMB 0651-0031 Patent and Trademark Office: U.S. Department of Commerce is it contains a valid OMB control number.
				Com	plete if Known
Substitute for form 1449A/PTO				Application No.	10/071,849
INFORM	IATIO	N DISCL	OSURE	Filing Date	02/07/2002
		BY APPL		First Named Inventor	Lyons
(Use d	as many sh	eets as necess	sary)	Art Unit	1623
				Examiner Name	Khare
Sheet	2	Of	2	Attorney Docket No.	12636.260

		OTHER PRIOR ART – NON PATENT RELATED DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published	T ²
		SHEIKHNEJAD, G. et al., "Mechanism of inhibition of DNA (cytosine C5)-methyltransferases by oligodeoxyribonucleotides containing 5,6-dihydro-5-azacytosine", <i>J. Mol. Biol.</i> , 1999, pages 2021-2034, Vol. 285.	
		GOFFIN, J. et al., "DNA methyltransferase inhibitors—state of the art", Annals of Oncology, 2002, pages 1699-1716, Vol. 13.	
,		WIJERMANS, P. et al., "Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients", <i>Journal of Clinical Oncology</i> , March 2000, pages 956-962, Vol. 18, No. 5	
·			
		·	
EXAMIN SIGNATU		DATE CONSIDERED	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.